Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Giovanni Scambia, Sandro Pignata, Domenica Lorusso, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna M. Mosconi, Michele Orditura, Alba A. Brandes, Valentina Arcangeli, Pierluigi Beneditti Panici, Carmela Pisano, Sabrina C. Cecere, Marilena Di Napoli, Francesco Raspagliesi, Giuseppa Maltese, Gennaro Daniele, Maria Carmela Piccirillo, Massimo Di Maio, Ciro GalloFrancesco Perrone

Research output: Contribution to journal › Article

87 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences